Abstract: The invention concerns an improved method for treating tumor, including cancer, which combines the administration of a chemotherapeutic agent and an antagonist of a gene product the expression of which is upregulated by the chemotherapeutic agent. The invention further concerns methods and means for the diagnosis and classification of tumors, and for the prognosis of the outcome of tumor treatment, and patient response to a particular treatment modality.
Abstract: A vector developed to transform fungi can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi. Systems and methods of using the vector are provided.
Type:
Grant
Filed:
March 25, 2009
Date of Patent:
April 3, 2012
Assignee:
National University Corporation Chiba University
Inventors:
Jon Ander Ochoa de Eribe Casas, Susumu Kawamoto
Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.
Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
Type:
Grant
Filed:
April 24, 2008
Date of Patent:
February 7, 2012
Assignee:
Sangamo Biosciences, Inc.
Inventors:
Russell DeKelver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
Abstract: Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein.
Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.
Type:
Grant
Filed:
August 21, 2008
Date of Patent:
September 6, 2011
Assignee:
The Resarch Foundation for Microbial Diseases of Osaka Universtiy
Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.
Type:
Grant
Filed:
August 21, 2008
Date of Patent:
September 6, 2011
Assignee:
The Research Foundation for Microbial Diseases of Osaka University
Abstract: An isolated polynucleotide molecule includes a DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus, wherein the DNA sequence is SEQ ID NO:1 or a degenerate variant thereof. Also provided are transformed or transfected host cells including that sequence, vectors including the sequence, and isolated infectious RNA molecules encoded by the sequence. Further, a modified DNA sequence encoding an infectious RNA molecule encoding a modified live viral strain of an Equine arteritis virus is provided wherein the DNA sequence is SEQ ID NO:2 or a degenerate variant thereof, including a silent point mutation allowing distinguishing the modified sequence from the parent and other strains of Equine arteritis virus.
Type:
Grant
Filed:
May 6, 2009
Date of Patent:
September 6, 2011
Assignee:
University of Kentucky Research Foundation
Inventors:
Udeni B. R. Balasuriya, Peter J. Timoney, Jianqiang Zhang
Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.
Type:
Grant
Filed:
September 5, 2006
Date of Patent:
August 30, 2011
Assignee:
The Research Foundation for Microbial Diseases of Osaka University
Abstract: Progressive multifocal leukoencephalopathy (PML) has been identified in patients taking natalizumab (NMAB) for the treatment of multiple sclerosis (MS). This patent application provides a novel method of patient screening and monitoring intended to decrease the risk of PML and other opportunistic central nervous system (CNS) diseases in patients undergoing MS therapy with NMAB, and proposes a novel method of screening and monitoring intended to decrease the risk of opportunistic disease processes of the CNS during the treatment of other medical disorders with NMAB.
Abstract: The invention provides recombinant DNA molecules comprising novel expression augmenting DNA fragments and an expression cassette, said expression cassette comprising a heterologous promoter linked to a nucleic acid of interest. The invention further provides uses of the novel expression augmenting DNA fragments. The invention further provides methods for obtaining novel expression augmenting DNA fragments.
Type:
Grant
Filed:
March 20, 2007
Date of Patent:
June 28, 2011
Assignee:
Chromagenics B.V.
Inventors:
Arie Pieter Otte, Henricus Johannes Maria Van Blokland, Theodorus Hendrikus Jacobus Kwaks, Richard George Antonius Bernardus Sewalt
Abstract: The invention relates to a method of detecting a DNA sequence which at least partially contributes to promote the stable expression of a gene. To this end the DNA fragment to be examined is cloned in a vector between i) a DNA sequence involved in the induction of gene transcription repressing chromatin and ii) a reporter gene. The invention also relates to the detected DNA sequence, and the application of a stable expression-enhancing DNA sequence for the stable expression of a gene.
Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.
Type:
Grant
Filed:
February 20, 2003
Date of Patent:
November 11, 2008
Assignee:
GlycoFi, Inc.
Inventors:
Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
Abstract: The present invention relates to a nucleotide sequence of a testis-specific gene in avian species and a method for identifying a testicular cell of avian species.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
September 23, 2008
Assignee:
Avicore Biotechnology Institute Inc.
Inventors:
Ji Hye Shin, Beom Ku Han, Heebal Kim, Jae Yong Han
Abstract: The present invention relates to expression control sequences of a vertebrate liver fatty acid binding protein (L-FABP) gene that, when operably linked to a reporter (e.g., a heterologous reporter, such as the green fluorescent protein (GFP)), directly express the reporter in a fashion that mimics the liver-specific development of the L-FABP gene in the vertebrate.
Abstract: This invention relates to methods and kits for determining the level of H2O2 inside a cell, and for determining whether a test compound has ability to scavenge a reactive oxygen species (ROS). The methods and diagnostic kits of this invention employ a cell containing a promoter which is inducible by an ROS, such as the H2O2 -inducible KatA promoter of Agrobacterium tumefaciens. The methods of this invention may also be used to select for new or improved ROS scavengers by expressing a library of test scavengers in cells which express a reporter from a ROS-inducible promoter and selecting for those cells whose level of ROS-inducible expression of the reporter is reduced.
Abstract: The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels.
Type:
Grant
Filed:
September 30, 2004
Date of Patent:
July 22, 2008
Assignee:
Ceres, Inc.
Inventors:
Zhihong Cook, Yiwen Fang, Ken Feldmann, Edward A Kiegle, Shing Kwok, Yu-Ping Lu, Leonard Medrano, Roger Pennell, Richard Schneeberger, Chuan-Yin Wu
Abstract: This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken ? actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (p?GLP1), carrying a furin cleavage site, which is constructed and delivered into a cell for the expression of active GLP-1.
Type:
Grant
Filed:
May 21, 2002
Date of Patent:
May 20, 2008
Assignee:
Expression Genetics, Inc.
Inventors:
Seungjoon Oh, Minhyung Lee, Kyungsoo Ko
Abstract: The present invention relates to an isolated mimetic of functional myostatin comprising part of the amino acid sequence of functional myostatin, such that the mimetic is capable of inhibiting muscle growth.
Type:
Grant
Filed:
January 18, 2001
Date of Patent:
May 6, 2008
Assignee:
Orico Limited
Inventors:
James Johnston Bass, Carole J. Berry, Ravi Kambadur, Mridula Sharma, Mark F. Thomas
Abstract: Markers for detecting and staging chondrogenesis in cells are provided. In one aspect the markers are isolated polynucleotides, referred to hereinafter as CZF-1 and CZF-2, and fragments thereof. In one embodiment, the CZF-1 polynucleotide comprises the open reading frame sequence set forth in SEQ ID NO.1. In one embodiment, the CZF-2 polynucleotide comprises the open reading frame sequence set forth in SEQ ID NO. 3. In another aspect the markers are antibodies, which are immunospecific for proteins encoded by CZF-1 or CZF-2. Methods which employ the present markers to identify cells that have begun to differentiate into chondrocytes are provided. The present invention also relates to the CZ-1 protein and the CZ-2 protein and to polynucleotides or oligonucleotides whose sequences are complementary to the coding sequences of CZF-1 or CZF-2, or regions thereof.